
Hyperthermia‐associated carboplatin resistance: Differential role of p53, HSF1 and Hsp70 in hepatoma cells
Author(s) -
Sharma Aanchal,
Meena Avtar Singh,
Bhat Manoj Kumar
Publication year - 2010
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2010.01516.x
Subject(s) - hsf1 , hsp70 , hyperthermia , heat shock , heat shock factor , heat shock protein , carboplatin , cancer research , biology , microbiology and biotechnology , chemistry , medicine , chemotherapy , genetics , cisplatin , gene
Due to substantial technical improvements, clinical application of heat as a co‐adjuvant in cancer treatment is acquiring new interest. The effect of hyperthermia on hepatoma cell lines Hep3B (p53 defective) and HepG2 (p53 wild type) when investigated led to an interesting observation that Hep3B cells are more susceptible to heat stress than HepG2 cells. In addition, heat‐induced carboplatin resistance was observed in HepG2 cells only. To investigate the reasons, heat shock response was explored and it was observed that heat stress augmented heat shock protein 70 (Hsp70) expression levels in HepG2 and not in Hep3B cells. Furthermore, in HepG2 cells, induced Hsp70 is regulated by both p53 and heat shock transcription factor 1 (HSF1) wherein HSF1 levels are modulated by p53. The data implies that Hep3B are more susceptible to death upon heat stress than HepG2 cells because of non‐induction of Hsp70. In addition, it was observed that inhibition of heat‐induced p53/HSF1 diminishes Hsp70 levels, thereby restoring the sensitivity of heat‐stressed HepG2 cells to carboplatin‐triggered cell death. Collectively, the present study establishes interplay of p53, HSF1, and Hsp70 upon heat stress in HepG2 cells and also defines novel strategies to overcome constraints of utility of hyperthermia in cancer therapy through p53/HSF1‐targeted therapeutic intervention. ( Cancer Sci 2010; 101: 1186–1193)